药物基本信息
通用名：贝伐珠单抗
临床用途：适用于转移性结直肠癌，主要联合以5-氟尿嘧啶为基础的化疗。
市场需求
贝伐珠单抗曾被誉为治疗转移性结直肠癌的“重磅炸弹”药物，被推荐作为多种适应症的一线治疗药物。2010年进入中国后市场表现良好，一直保持在亿元以上。2016全国销售额约18亿元，年增长率35.92%。
The basic information of drug
common name: Bevacizumab
Indications: Treatment of metastatic colorectal cancer, mainly combined with 5-fluorouracil-based chemotherapy.
Market demand
Bevacizumab was known as a "blockbuster" drug for the treatment of metastatic colorectal cancer and was recommended as a first-line treatment for multiple indications. After entering China in 2010, the market performed well and remained above $ 100 million. In 2016, the national sales are about 1.8 billion, and annual growth rate is 35.92%.
（贝伐珠单抗作用机制，图片来源新药汇）
